FILTRATION AND ADSORPTION REGIONE EMILIA-ROMAGNA
Selective blood clearance must and can become an ever more intelligent process. Develop new clearance technologies that overcome the albumin wall and drive towards adsorption therapies aimed at extracorporeal treatments for complex diseases: this is the commitment of the Collaborative Research by universities, clinics and the industry.
This is also testified by the F.A.R.E. Project, dedicated to creating a system for extracorporeal blood clearance capable of overcoming the technological restrictions that today preclude or drastically reduce the clinical practice. The priority objective of this project is the treatment of highly crippling diseases such as: simple or complex acute renal failure, septic shock, rheumatoid arthritis, myeloma and crush syndrome (diseases for which researchers are choosing the road of blood clearance as therapeutic treatment).
In particular, the Laboratory programme is dedicated to the design of new filtration technologies and adsorption systems capable of holding back harmful substances of medium- to high-molecular weight and giving back nutritious factors to the blood.
Bellco provides the Laboratory with its know-how of adsorption technologies and integrated therapeutic process management and Medica its know-how of filtration systems. Moreover, three distinguished research teams of the University of Modena and Reggio Emilia are actively working on this project providing their expertise and resources.
The seeds for the project were sown with two treatments developed by Bellco: HFR (Haemodiafiltration with Endogenous Reinfusion) and CPFA (Coupled Plasma Filtration and Adsorption). HFR uses a dual-chamber dialysing filter and a sorbent resin cartridge, which allows adsorbing low- and medium-molecular-weight substances and reinfusing albumin, amino acids and vitamins to the patient.
CPFA uses a plasma filter, which allows running the plasma through a cartridge where the resin holds back toxins of different molecular weight and reinfusing beneficial substances to the patient.
The aim of the research is to specifically identify the molecules to be cleared and reinfused, designing suitable membranes, defining the specific sorbents for the various molecules and providing adequate control systems to automatically manage the entire process for clinical practice.